BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

14 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
3
Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.EBI
University of Toronto At Mississauga
17
Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway.EBI
AstraZeneca
15
Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.EBI
Johnson & Johnson Pharmaceutical Research & Development
53
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader.EBI
University of Michigan
5
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.EBI
Mayo Clinic
29
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity EBI
University of Michigan
37
Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.EBI
Ewha Womans University
21
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.EBI
China Pharmaceutical University
15
Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.EBI
Cancer Hospital of The University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
2
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.EBI
University of Michigan
3
A small-molecule screen identifies the antitrypanosomal agent suramin and analogues NF023 and NF449 as inhibitors of STAT5a/b.EBI
Leipzig University
14
Halogen-substituted catechol bisphosphates are potent and selective inhibitors of the transcription factor STAT5b.EBI
Leipzig University
18
Compounds as neuronal histamine receptor-3 antagonists and uses thereofBDB
Xwpharma
1
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB
Sanofi Recherche